Giacobini E
Department of Geriatrics, University Hospitals of Geneva, Switzerland.
J Physiol Paris. 1998 Jun-Aug;92(3-4):283-7. doi: 10.1016/s0928-4257(98)80034-x.
Cholinesterase inhibitors (ChEI) represent the drug of choice for Alzheimer's disease (AD) treatment. They produce significant improvement on cognitive as well as non-cognitive function for a period up to 1 year during the first 3 years following clinical diagnosis. The magnitude of cognitive improvements is similar for different ChEI, however, differences are seen with regard to incidence and severity of side effects, optimal ChE inhibition, pharmacokinetic properties and mode of administration.
胆碱酯酶抑制剂（ChEI）是治疗阿尔茨海默病（AD）的首选药物。在临床诊断后的前3年中，它们可在长达1年的时间内显著改善认知功能和非认知功能。不同的胆碱酯酶抑制剂在认知改善程度上相似，然而，在副作用的发生率和严重程度、最佳胆碱酯酶抑制效果、药代动力学特性及给药方式方面存在差异。
